TVM Capital Life Science Announces Substantially Oversubscribed US$478 Million Final Closing of TVM Life Science Innovation II, largest fund in the firm's history

PR86275

MUNICH and MONTREAL, Oct. 27, 2020 /PRNewswire=KYODO JBN/ --

- The Fund continues the proven "Project Focused Company" investment strategy

for early-stage drug development candidates

- In addition, the Fund continues to invest in late-stage clinical

biopharmaceutical companies, medical device companies and diagnostic companies

TVM Capital Life Science, one of the leading life sciences venture capital

firms in North America and Europe, today announced the final closing of its

latest fund, TVM Life Science Innovation II (TVM LSI II). Committed capital

totals US$478 million which was raised from high profile international

investors, including Eli Lilly and Company, other strategic investors, pension

funds, endowments, foundations, fund-of-funds, wealth managers and large US

banks as well as multi and single family offices from the Americas, Europe and

South Korea. The geographical focus for the Fund's investment activity is on

North-America and Europe.

TVM LSI II was substantially oversubscribed. The Fund already sold its first

investment in February 2020.

TVM LSI II will maintain TVM's focus on investing in assets that provide a

visible and attractive exit strategy from the outset with the goal of

maximizing returns and providing early and significant liquidity for its

investors. About 50-60% of the Fund's capital is intended to be invested in

"Project Focused Companies" ("PFCs") which are majority-owned by the Fund and

set up for the development of early-stage drug candidates in a capital and time

efficient manner. The remaining capital will be invested in late clinical stage

biopharmaceutical companies as well as commercial stage medical device and

diagnostic companies. The proven focus of TVM LSI II continues on building a

portfolio of differentiated first-in-class and best-in-class assets that are

diversified by indication and stage of development.

Dr. Luc Marengere, Managing Partner of TVM Capital Life Science commented: "We

are thrilled by the strong support of existing and new investors in TVM LSI II.

TVM LSI II is the largest fund raised by TVM since inception. In addition, we

are grateful for the pivotal role in raising TVM LSI II in the Americas and

Europe by New York based OCP and Founder Joelle Wyser-Pratte."

Stefan Fischer, Managing Partner (Finance) stated: "We are confident that TVM

LSI II will not only continue the TVM success story for our investors but will

also enable the financing of the development of new and differentiated

treatment options for patients with significant unmet medical needs."

"The success of this fundraising effort is a strong validation of the

innovative, capital-efficient investment strategy that we have implemented in

2012 together with Eli Lilly and Company. TVM LSI II intends to make

investments in about 16 early-stage single asset PFCs and 10 late-stage

companies with a focus on North America and Europe," wrote Dr. Hubert Birner,

Managing Partner of TVM Capital Life Science based in Munich.

With the closing of TVM LSI II, Stefan Fischer was promoted to Managing Partner

(Finance) and Dr. Sascha Berger was promoted to Partner.

In the past few months, the TVM investment team was complemented with the

addition of Alexandra MacLean, MD and Alain Thibault, MD as Principals and, Dr.

Valentina Agostina, Catello Somma and Philipp Lechner as Associates.

About TVM Capital Life Science

TVM Capital Life Science provides venture capital to international

biopharmaceutical, medical technology, and diagnostic companies in North

America and the EU. TVM follows a two-pronged strategy with a focus on early

and late stage investments.

www.tvm-lifescience.com.

Contacts:

Media/Press:

TVM Capital Life Science: Stefan Fischer, Managing Partner (Finance), TVM

Capital Life Science, fischer@tvm-capital.com, +49 89 998 992 36

Investors:

OCP Capital: Joelle Wyser-Pratte, Founder, joelle@ocpcap.com, +1 914 441 3554

General Partner

TVM Life Science Innovation II (GP) S. à r.l.

8, Rue Lou Hemmer

L-1748, Senningerberg

Grand Duchy of Luxembourg

Investment Advisor

TVM Life Science Management Inc.

2 Place Alexis Nihon, Suite 902, Montréal, QC H3Z 1X5, Canada

TVM Life Science Management GmbH

Ottostrasse 4

80333 Munich

Germany

Logo -

https://mma.prnewswire.com/media/1319854/TVM_Capital_Life_Science_Logo.jpg 

Source: TVM Capital Life Science